DMT
A potent, short-acting psychedelic tryptamine producing intense visionary experiences, naturally found in plants and mammals.
EEG-fMRI studies in healthy volunteers demonstrate that IV DMT (20 mg) produces robust increases in global functional connectivity, network disintegration, and compression of the principal cortical gradient, with effects correlating to 5-HT2A receptor density maps. Recent research has identified DMT levels in rodent brains comparable to classical neurotransmitters, challenging earlier assumptions of trace-only concentrations and suggesting a potential endogenous neurotransmitter role. Preclinical studies indicate DMT may protect against ischemia-reperfusion injury and neurodegeneration via sigma-1 receptor activation, and may promote neuroplasticity, neurogenesis, and immunomodulation. However, clinical evidence in humans remains limited, with most therapeutic data coming from observational studies or surrogate compounds like 5-MeO-DMT rather than controlled DMT trials. Acute sympathomimetic side effects, including hypertension and tachycardia, have been documented and may limit therapeutic applicability without coformulation strategies.